Does Rallies show 13F holders for IGC?

Yes. Rallies tracks hedge fund and 13F ownership data for IGC, including fund names, share counts, latest tracked quarter, and position changes when available.

Is IGC research on Rallies investment advice?

No. Rallies provides research, data, and educational context for IGC. It does not provide personalized investment advice.

IGC (IGC Pharma, Inc.) Stock Analysis - Hedge Fund Holdings

IGC Pharma, Inc. (IGC) is a publicly traded Industrials sector company. As of May 20, 2026, IGC trades at $0.30 with a market cap of $28.26M and a P/E ratio of -3.08. IGC moved -1.43% today. Year to date, IGC is -3.09%; over the trailing twelve months it is -9.00%. Its 52-week range spans $0.24 to $0.50. Analyst consensus is buy with an average price target of $5.25. Rallies surfaces IGC's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns IGC stock?

Hedge funds tracked by Rallies that own IGC include Two Sigma and Citadel Advisors. The latest tracked quarter is Dec 31, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for IGC Pharma, Inc..

IGC Key Metrics

Key financial metrics for IGC
Metric	Value
Price	$0.30
Market Cap	$28.26M
P/E Ratio	-3.08
EPS	$-0.09
Dividend Yield	0.00%
52-Week High	$0.50
52-Week Low	$0.24
Volume	642.81K
Avg Volume	0
Revenue (TTM)	$1.27M
Net Income	$-7.12M
Gross Margin	48.70%

Top Hedge Funds Holding IGC

Two Sigma holds 60.86K shares of IGC, changed -38.53% as of Dec 31, 2024.
Citadel Advisors holds 3.07K shares of IGC, changed +155.67% as of Dec 31, 2024.

Latest IGC News

IGC Pharma Reaches 80% Enrollment in Phase 2 CALMA Trial and Posts Q1 Results — May 19, 2026
IGC Pharma Showcases Shannon Entropy Tau-PET Analysis on 1,570 Scans at Global Tau Conference — May 15, 2026
IGC Pharma Sees 80% Enrollment in Phase 2 CALMA Alzheimer’s Agitation Trial — Apr 28, 2026
IGC Pharma Secures Psilocybin License, Targets Depression and Anxiety in Dementia — Apr 20, 2026
IGC Pharma Price Target Lifted to $5.25 on Phase 2 CALMA Data — Apr 8, 2026

Recent IGC Insider Trades

Moran James P bought 588.24K (~$200.00K) on Sep 25, 2024.
PRINS RICHARD K sold 50.00K (~$87.50K) on Mar 9, 2021.
PRINS RICHARD K sold 500 (~$905) on Mar 3, 2021.

IGC Analyst Consensus

1 analysts cover IGC: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $5.25.

Common questions about IGC

Who owns IGC stock?: Hedge funds tracked by Rallies that own IGC include Two Sigma and Citadel Advisors. The latest tracked quarter is Dec 31, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for IGC Pharma, Inc..
Does Rallies show 13F holders for IGC?: Yes. Rallies tracks hedge fund and 13F ownership data for IGC, including fund names, share counts, latest tracked quarter, and position changes when available.
Is IGC research on Rallies investment advice?: No. Rallies provides research, data, and educational context for IGC. It does not provide personalized investment advice.